Augmenta - TFF Pharma's COVID-19 Antibody Shows Preclinical Activity Against Delta Variant

  • Augmenta Bioworks and TFF Pharmaceuticals Inc TFFP have announced positive in vitro data indicating that their lead anti-COVID-19 monoclonal antibody, AUG-3387, binds to and neutralizes the SARS-CoV-2 Delta variant (B.1.617.2). 
  • The companies have selected a final formulation of AUG-3387 that will be used to complete in vivo preclinical efficacy studies in the coming weeks and will proceed with toxicology studies by the end of 2021. 
  • Ongoing formulation development studies are expected to demonstrate that a sufficient dose of AUG-3387 to achieve a neutralizing concentration in the lungs can be delivered via already approved commercial dry powder inhaler devices.
  • Price Action: TFFP shares are up 1.50% at $8.78 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsSARS-CoV-2
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!